Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy

Outcome Description:

Serum samples were collected for HCV RNA. The change from initiation of Pegasys plus Copegus to Week 12 in HCV RNA titers were calculated. Randomization for the with Pioglitazone arm occurred prior to the 16 week run-in period and randomization for the without Pioglitazone arm occurred prior to the start of anti-HCV treatment.

Outcome Time Frame:

Initiation of Pegasys plus Copegus, Week 12 of anti-HCV treatment

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

United States: Food and Drug Administration

Study ID:

ML21301

NCT ID:

NCT00545233

Start Date:

January 2008

Completion Date:

December 2010

Related Keywords:

• Hepatitis C, Chronic
• Hepatitis
• Hepatitis A
• Hepatitis, Chronic
• Hepatitis C
• Insulin Resistance
• Hepatitis C, Chronic